Open AccessHigh-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial
Author(s) -
Anders Olsson,
Gregory G. Schwartz,
Michael Szarek,
William J. Sasiela,
Michael D. Ezekowitz,
Patricia A. Ganz,
M.F. Oliver,
David D. Waters,
Andreas M. Zeiher
Publication year - 2005
Publication title -
european heart journal
Language(s) - English
Resource type - Journals
eISSN - 1522-9645
pISSN - 0195-668X
DOI - 10.1093/eurheartj/ehi186
Subject(s) - medicine , atorvastatin , acute coronary syndrome , hazard ratio , randomization , cholesterol , cardiology , lipoprotein , clinical endpoint , proportional hazards model , clinical trial , endocrinology , myocardial infarction , confidence interval
Patients with acute coronary syndrome (ACS) in the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study had diminished cardiovascular events after 16 weeks of treatment of atorvastatin 80 mg daily. We determined whether plasma lipoproteins at baseline and then at 6 weeks after randomization predicted clinical outcome.